Organon & Co. (NYSE:OGN) Receives $8.38 Consensus Price Target from Brokerages

Organon & Co. (NYSE:OGN) has earned a consensus recommendation of “Reduce” from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $8.3750.

OGN has been the topic of a number of analyst reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of Organon & Co. in a research note on Wednesday, October 8th. JPMorgan Chase & Co. reduced their target price on Organon & Co. from $14.00 to $12.00 and set an “underweight” rating for the company in a report on Tuesday, November 11th. Piper Sandler downgraded shares of Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 price target on the stock. in a report on Monday, October 27th. Wall Street Zen upgraded shares of Organon & Co. from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. Finally, Barclays started coverage on shares of Organon & Co. in a report on Tuesday, December 9th. They set an “underweight” rating and a $7.50 target price on the stock.

Institutional Investors Weigh In On Organon & Co.

Several large investors have recently added to or reduced their stakes in OGN. Vanguard Group Inc. increased its stake in Organon & Co. by 11.3% in the 3rd quarter. Vanguard Group Inc. now owns 35,928,403 shares of the company’s stock worth $383,715,000 after acquiring an additional 3,650,860 shares during the last quarter. State Street Corp grew its holdings in shares of Organon & Co. by 6.0% during the second quarter. State Street Corp now owns 9,520,594 shares of the company’s stock worth $92,159,000 after purchasing an additional 540,478 shares in the last quarter. Nordea Investment Management AB grew its holdings in shares of Organon & Co. by 1.1% during the second quarter. Nordea Investment Management AB now owns 4,904,076 shares of the company’s stock worth $48,281,000 after purchasing an additional 53,733 shares in the last quarter. AQR Capital Management LLC increased its position in shares of Organon & Co. by 28.3% in the third quarter. AQR Capital Management LLC now owns 4,176,144 shares of the company’s stock worth $43,641,000 after purchasing an additional 921,260 shares during the last quarter. Finally, Gotham Asset Management LLC increased its position in shares of Organon & Co. by 37.2% in the third quarter. Gotham Asset Management LLC now owns 3,713,204 shares of the company’s stock worth $39,657,000 after purchasing an additional 1,007,691 shares during the last quarter. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Price Performance

OGN opened at $8.43 on Friday. The firm has a 50-day moving average price of $7.36 and a 200-day moving average price of $8.79. Organon & Co. has a twelve month low of $6.18 and a twelve month high of $17.23. The company has a quick ratio of 1.20, a current ratio of 1.75 and a debt-to-equity ratio of 9.69. The company has a market capitalization of $2.19 billion, a price-to-earnings ratio of 4.39, a PEG ratio of 1.68 and a beta of 0.58.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Monday, November 10th. The company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.93 by $0.08. The company had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Organon & Co. had a net margin of 7.95% and a return on equity of 143.47%. During the same period in the prior year, the company posted $1.38 EPS. Equities analysts expect that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, December 11th. Stockholders of record on Thursday, November 20th were issued a $0.02 dividend. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $0.08 annualized dividend and a dividend yield of 0.9%. Organon & Co.’s dividend payout ratio is presently 4.17%.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.